Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclic AMP has the ability to influence multiple events during B cell stimulation.

H Holte1, P Torjesen, H K Blomhoff

  • 1Department of Pathology, Institute for Cancer Research, Oslo, Norway.

European Journal of Immunology
|September 1, 1988
PubMed
Summary

Forskolin inhibits normal and neoplastic B cell activation by affecting both early and late stages. This cyclic adenosine monophosphate (cAMP) elevating agent impacts B cell proliferation and DNA synthesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.

Leukemia & lymphoma·2023
Same author

Executive Function and Psychosocial Adjustment in Adolescent Survivors of Pediatric Brain Tumor.

Developmental neuropsychology·2021
Same author

Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.

European journal of cancer (Oxford, England : 1990)·2020
Same author

Self-reported late effects and long-term follow-up care among 1889 long-term Norwegian Childhood, Adolescent, and Young Adult Cancer Survivors (the NOR-CAYACS study).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020
Same author

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Blood cancer journal·2017
Same author

Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.

Bone marrow transplantation·2016

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Cellular proliferation requires balanced growth control, with negative regulators playing a key role.
  • B cell activation is a complex process involving multiple signaling pathways.
  • Adenosine 3',5'-cyclic monophosphate (cAMP) is a crucial second messenger influencing cellular functions, including B cell stimulation.

Purpose of the Study:

  • To investigate the effects of forskolin, a diterpene that elevates intracellular cAMP levels, on various parameters of human B cell activation.
  • To determine if forskolin's inhibitory effects on B cell activation differ between normal and neoplastic cells.

Main Methods:

  • Human B cells were stimulated using antibodies to surface immunoglobulins (anti-mu), the CD20-reactive antibody 1F5, or 12-O-tetradecanoylphorbol 13-acetate.

Related Experiment Videos

  • Forskolin was added at different time points to assess its impact on early and late activation events.
  • Measurements included phosphatidylinositol (PI) turnover, intracellular calcium ([Ca2+]i) fluxes, G1 entry, and DNA synthesis.

    • Main Results:

    • Forskolin significantly inhibited early events (PI turnover, [Ca2+]i fluxes) and late events (G1 entry, DNA synthesis) of B cell activation, regardless of the stimulation pathway (PI/Ca2+-dependent or independent).
    • The inhibitory effect of forskolin was observed even when added late in the activation process, suggesting interference at multiple stages.
    • Neoplastic B cells exhibited similar sensitivity to forskolin's inhibitory effects as normal B cells.

    Conclusions:

    • Forskolin, by elevating cAMP, acts as a potent negative regulator of both normal and neoplastic B cell activation.
    • cAMP influences B lymphocyte stimulation through multiple mechanisms, affecting both early signaling and later proliferative events.
    • These findings highlight the potential of cAMP-modulating agents in controlling B cell proliferation.